Dyadic International
Developer and licensor of filamentous fungal microbial expression platforms for production of recombinant proteins and enzymes at laboratory through commercial scale. Focus areas include animal‑origin‑free proteins for life sciences, food & nutrition, and bio‑industrial applications, delivered via partner manufacturing, licensing, and collaborative programs.
Industries
Nr. of Employees
medium (51-250)
Dyadic International
Patents
Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
US-9862956-B2
View DetailsMultimeric protein for fermentation of ethanol from pla nt biomass; enhancing quality of animal feeds
US-8304212-B2
View Details
Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
US-9862956-B2
View DetailsMultimeric protein for fermentation of ethanol from pla nt biomass; enhancing quality of animal feeds
US-8304212-B2
View DetailsProducts
Recombinant human albumin — partner-manufactured commercial product
Animal‑origin‑free recombinant human albumin produced via microbial expression and launched commercially through a manufacturing and distribution partner.
Animal‑origin‑free recombinant DNase I (RNase‑free) — research grade
Recombinant DNase I produced in microbial systems for nucleic‑acid cleanup and sample preparation with RNase‑free specification for RNA workflows.
Recombinant chymosin for dairy processing — planned commercialization
Microbially produced chymosin intended as a non‑animal‑derived enzyme for cheese manufacturing and dairy processing.
Recombinant transferrin and growth factors (development pipeline)
Animal‑free transferrin and growth factors targeting cell culture media, cultivated meat, and biomanufacturing applications; development, sampling, and early commercial engagement reported.
Pulp & Paper
Enzymes that enhance fiber treatment, deinking, and energy efficiency in paper production.
Pulp & Paper Cocktail
Industrial-grade glycolytic enzyme used in pulp & paper and biomass conversion.
Recombinant human albumin — partner-manufactured commercial product
Animal‑origin‑free recombinant human albumin produced via microbial expression and launched commercially through a manufacturing and distribution partner.
Animal‑origin‑free recombinant DNase I (RNase‑free) — research grade
Recombinant DNase I produced in microbial systems for nucleic‑acid cleanup and sample preparation with RNase‑free specification for RNA workflows.
Recombinant chymosin for dairy processing — planned commercialization
Microbially produced chymosin intended as a non‑animal‑derived enzyme for cheese manufacturing and dairy processing.
Recombinant transferrin and growth factors (development pipeline)
Animal‑free transferrin and growth factors targeting cell culture media, cultivated meat, and biomanufacturing applications; development, sampling, and early commercial engagement reported.
Pulp & Paper
Enzymes that enhance fiber treatment, deinking, and energy efficiency in paper production.
Pulp & Paper Cocktail
Industrial-grade glycolytic enzyme used in pulp & paper and biomass conversion.
Services
Licensing of microbial expression platforms and provision of R&D support for partner protein expression, strain development, and scale-up.
Support for downstream process development and scale-up through collaborations with manufacturing partners and CMOs to enable commercial production.
Commercial launch support, regional distribution partnerships, and revenue‑sharing or licensing arrangements to accelerate market entry for recombinant protein inputs.
Licensing of microbial expression platforms and provision of R&D support for partner protein expression, strain development, and scale-up.
Support for downstream process development and scale-up through collaborations with manufacturing partners and CMOs to enable commercial production.
Commercial launch support, regional distribution partnerships, and revenue‑sharing or licensing arrangements to accelerate market entry for recombinant protein inputs.
Expertise Areas
- Recombinant protein production using fungal hosts
- Microbial fermentation scale-up and process transfer
- Downstream purification and bioprocess development
- Analytical and biophysical characterization of protein therapeutics and reagents
Key Technologies
- Filamentous fungal expression
- Precision fermentation
- Microbial fermentation and bioreactor scale-up
- Codon optimization and rapid strain generation
News & Updates
Company announced a webcast and conference call to report financial results for the year ended December 31, 2025 and provide a corporate update.
Announcement of commercial launch of partner-manufactured recombinant human albumin for cell culture, diagnostic, and research markets.
Expanded agreement enabling third‑party manufacture and commercialization of an expanding portfolio of animal‑free proteins and enzymes and providing dual‑sourcing and co‑commercialization capabilities.
Agreement with a regional commercialization partner to accelerate market entry for recombinant transferrin and growth factor products in targeted territories.
Agreement to jointly develop and commercialize recombinant alpha-lactalbumin for nutrition markets with milestone and revenue participation provisions.
Quarterly financial results and summary of strategic pivot toward commercial focus, licensing updates, and program milestones.
Company announced a webcast and conference call to report financial results for the year ended December 31, 2025 and provide a corporate update.
Announcement of commercial launch of partner-manufactured recombinant human albumin for cell culture, diagnostic, and research markets.
Expanded agreement enabling third‑party manufacture and commercialization of an expanding portfolio of animal‑free proteins and enzymes and providing dual‑sourcing and co‑commercialization capabilities.
Agreement with a regional commercialization partner to accelerate market entry for recombinant transferrin and growth factor products in targeted territories.
Agreement to jointly develop and commercialize recombinant alpha-lactalbumin for nutrition markets with milestone and revenue participation provisions.
Quarterly financial results and summary of strategic pivot toward commercial focus, licensing updates, and program milestones.